Chapter 26. Leukotrienes in COPD: The Unexploited Potential

  1. Robert A. Stockley Professor1,
  2. Stephen I. Rennard Professor2,
  3. Klaus Rabe Professor3 and
  4. Bartolome Celli Professor4
  1. Sven-Erik Dahlén

Published Online: 11 JAN 2008

DOI: 10.1002/9780470755976.ch26

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

How to Cite

Stockley, R. A., Rennard, S. I., Rabe, K. and Celli, B. (2007) Leukotrienes in COPD: The Unexploited Potential, in Chronic Obstructive Pulmonary Disease, Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470755976.ch26

Author Information

  1. 1

    Professor of Medicine, Department of Medicine, Queen Elizabeth Hospital, Birmingham, B15 2TH, UK

  2. 2

    Pulmonary & Critical Care Medicine Section, University of Nebraska Medical Center, 985125 Nebraska Medical Center, 800 South 42nd Street, Omaha, NE 68198-5300

  3. 3

    Dept of Pulmonology, Leiden Universtiy Medical Centre, Albinusdreef 2, C3-P, Postbox 9600, 2300 RC, Leiden, Netherlands

  4. 4

    Division of Pulmonary and Critical Care, St Elizabeth's Medical Centre, 736 Cambridge Street, Tufts University, Boston, MA 02135-2907

Publication History

  1. Published Online: 11 JAN 2008
  2. Published Print: 1 JAN 2007

ISBN Information

Print ISBN: 9781405122894

Online ISBN: 9780470755976



  • leukotrienes;
  • biosynthesis;
  • immunoglobulin E;
  • antileukotriene drugs;
  • pharmacology


This chapter contains sections titled:

  • Biosynthesis, receptors and metabolism

  • Biological actions of leukotrienes with relevance to the respiratory system

  • Pharmacology of antileukotrienes

  • Lessons to be learned from the effects of antileukotrienes in the treatment of asthma:questions for COPD research

  • Conclusions and perspective

  • Acknowledgements

  • References